Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Intranasal vaccination

Cell Rep. (2021)

Intranasal vaccination can have several advantages over conventional intramuscular vaccines, not least because they can generate strong immune responses at key sites of pathogen exposure such as the lungs. In Cell Reports, Diamond and colleagues use a chimpanzee adenoviral-vectorized vaccine that expresses the CoV-2 spike protein (ChAd-SARS-CoV-2-S) and investigate the durability, dose response and cross-protective effects in humanized mice after intranasal administration. A single intranasal dose of vaccine induced humoral responses that were superior to the intramuscular route both in terms of antibody titer and neutralizing efficacy. Intranasal vaccine also generated long-lived plasma cells in the bone marrow that were absent or minimally present with intramuscular dosing. Notably, intranasal vaccination protected against variants of concern such as B.1.351 (Beta) for up to 9 months.

Author information



Corresponding author

Correspondence to Zoltan Fehervari.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fehervari, Z. Intranasal vaccination. Nat Immunol 22, 1071 (2021).

Download citation


Quick links